Edinburgh Research Explorer

A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension

Research output: Contribution to journalArticlepeer-review

  • Nadine D Arnold
  • Josephine A Pickworth
  • Laura E West
  • Sarah Dawson
  • Joana A Carvalho
  • Helen Casbolt
  • Adam T Braithwaite
  • James Iremonger
  • Lewis Renshall
  • Volker Germaschewski
  • Matthew McCourt
  • Philip Bland-Ward
  • Hager Kowash
  • Abdul G Hameed
  • Alexander M K Rothman
  • Maria G Frid
  • A A Roger Thompson
  • Holly R Evans
  • Mark Southwood
  • Nicholas W Morrell
  • David C Crossman
  • Kurt R Stenmark
  • Christopher M Newman
  • David G Kiely
  • Sheila E Francis
  • Allan Lawrie

Related Edinburgh Organisations

Open Access permissions



  • Download as Adobe PDF

    Rights statement: Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

    Final published version, 3.73 MB, PDF document

    Licence: Creative Commons: Attribution (CC-BY)

Original languageEnglish
Pages (from-to)5183
JournalNature Communications
Issue number1
Early online date15 Nov 2019
Publication statusE-pub ahead of print - 15 Nov 2019


Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Current treatments increase life expectancy but have limited impact on the progressive pulmonary vascular remodelling that drives PAH. Osteoprotegerin (OPG) is increased within serum and lesions of patients with idiopathic PAH and is a mitogen and migratory stimulus for pulmonary artery smooth muscle cells (PASMCs). Here, we report that the pro-proliferative and migratory phenotype in PASMCs stimulated with OPG is mediated via the Fas receptor and that treatment with a human antibody targeting OPG can attenuate pulmonary vascular remodelling associated with PAH in multiple rodent models of early and late treatment. We also demonstrate that the therapeutic efficacy of the anti-OPG antibody approach in the presence of standard of care vasodilator therapy is mediated by a reduction in pulmonary vascular remodelling. Targeting OPG with a therapeutic antibody is a potential treatment strategy in PAH.

Download statistics

No data available

ID: 131463243